The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

EXTON, PA / ACCESSWIRE / November 12, 2024 / Frontage Laboratories, Inc ., a global CRO, and Medicover Integrated Clinical ...

Myriad Genetics and agency partner S50 Health educated OBGYNs and their patients in a campaign called “Getting Ahead of ...

Analyst Puneet Souda of Leerink Partners maintained a Buy rating on Myriad Genetics (MYGN – Research Report), reducing the price target ...

In 2014, Dunlop won a famous case involving breast cancer tests where competitor Myriad Genetics claimed it could patent ...

Q3 2024 Earnings Call Transcript November 7, 2024 Pacific Biosciences of California, Inc. beats earnings expectations.

Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Investigation Details On October 31, 2024, it was revealed that UnitedHealth Group (“UnitedHealth”) would no longer cover GeneSight, Myriad’s genetic test to help determine which mental health ...

1 On November 1, 2024, UnitedHealthcare ("UNH") updated its medical policy for commercial and individual exchange plans to ...

Global Breast Cancer Screening Tests Market was valued at approximately USD 2.93 billion in 2023 and is projected to grow with a healthy CAGR of 54.3% over the forecast period 2024-2032. Read the ...